Compare AVX & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVX | NKTX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 132.8M |
| IPO Year | 2021 | 2020 |
| Metric | AVX | NKTX |
|---|---|---|
| Price | $0.70 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | ★ 1.6M | 821.7K |
| Earning Date | 11-14-2025 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,319,011.00 | N/A |
| Revenue This Year | $530,767.50 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8001.54 | N/A |
| 52 Week Low | $0.60 | $1.31 |
| 52 Week High | $22.50 | $2.74 |
| Indicator | AVX | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.12 | 42.32 |
| Support Level | $0.63 | $1.91 |
| Resistance Level | $0.77 | $2.13 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 5.69 | 7.70 |
AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. The company focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.